CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 1,015 enrolled
Drug / intervention
Heparindrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00237328
NCT00237328N/ACompleted
CompareCT.gov

The Incidence of Thromboembolic Events in Patients With Antibodies to Heparin-PF4 After Cardiac Bypass

Duke University·observational·Posted Oct 12, 2005·Updated Feb 25, 2013

In Brief

An observational study evaluating Heparin for Thrombosis. Completed, enrolled 1,015 participants across 4 sites.

Detailed Summary

Heparin is a drug that is widely used to prevent and treat blood clotting. Individuals undergoing cardiopulmonary bypass surgery are administered high doses of heparin, and some of them develop antibodies to the drug. This immune response can lead to the formation of blood clots, setting the stage for a potential heart attack or stroke. The purpose of this study is to evaluate how often an immune response to heparin leads to the formation of blood clots in individuals who have had heart surgery.

Study Details

Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsThrombosis
CountriesUnited States
Collaborators--

Timeline

N/ACompletedFinished
2006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedOct 12, 2005
Enrollment StartJun 1, 2006
Primary CompletionMar 1, 2009
Study CompletionJul 1, 2012
TodayJul 2, 2026
Enrollment to primary: 2.8 yearsPosted 20.7 years ago

Interventions

Heparindrug

Heparin will be used as the intra-operative anticoagulant